The ROE as of November 2024 (TTM) for Liquidia Corporation (LQDA) is -155.77%

According to Liquidia Corporation’s latest financial reports and current stock price. The company's current ROE is -155.77%. This represents a change of 264.40% compared to the average of -42.75% of the last 4 quarters.

Liquidia Corporation (LQDA) Historical ROE (quarterly & annually)

How has LQDA ROE performed in the past?

The mean historical ROE of Liquidia Corporation over the last ten years is -45.97%. The current -155.77% ROE has changed 238.88% with respect to the historical average. Over the past ten years (40 quarters), LQDA's ROE was at its highest in in the March 2018 quarter at 686.01%. The ROE was at its lowest in in the June 2020 quarter at -156.90%.

Liquidia Corporation (LQDA) ROE by Quarter and Year

Discovering the peaks and valleys of Liquidia Corporation ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Liquidia Corporation (LQDA) Average ROE

How has LQDA ROE performed in the past?

The current ROE of Liquidia Corporation (LQDA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Liquidia Corporation (LQDA) ROE vs. Peers

How is LQDA’s ROE compared to its peers?

Liquidia Corporation’s ROE is less than BioMarin Pharmaceutical Inc. (6.22%), greater than Vaxcyte, Inc. (-23.53%), greater than Legend Biotech Corporation (-29.69%), less than Bio-Techne Corporation (7.36%), less than United Therapeutics Corporation (19.22%), greater than Geron Corporation (-67.53%), less than NRx Pharmaceuticals, Inc. (127.35%), less than Agenus Inc. (131.89%), greater than Replimune Group, Inc. (-53.12%), greater than Nuvectis Pharma, Inc. (-155.80%), greater than Lyra Therapeutics, Inc. (-178.68%), greater than Kronos Bio, Inc. (-64.55%), greater than Gossamer Bio, Inc. (-127.28%), greater than Terns Pharmaceuticals, Inc. (-32.76%), greater than Amylyx Pharmaceuticals, Inc. (-85.39%), greater than Acumen Pharmaceuticals, Inc. (-32.99%), greater than Inozyme Pharma, Inc. (-88.42%), greater than X4 Pharmaceuticals, Inc. (-32.51%), greater than Immunocore Holdings plc (-14.67%), greater than Mirum Pharmaceuticals, Inc. (-41.22%), greater than Larimar Therapeutics, Inc. (-35.87%), greater than KalVista Pharmaceuticals, Inc. (-97.37%),

Build a custom stock screener for Liquidia Corporation (LQDA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Liquidia Corporation using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Liquidia Corporation (LQDA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Liquidia Corporation or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.